Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
130 participants
INTERVENTIONAL
2016-05-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes
NCT04170517
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
NCT05980091
Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.
NCT02032797
Pregnancy Outcomes of Patients Having NC-FET Regarding the Progesterone Levels
NCT05690360
Serum Progesterone on the Day of Embryo Transfer and Pregnancy Rate.
NCT03272412
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The regulation of synchrony between embryo and endometrium has not been fully addressed clinically in the human. This limitation affects IVF significantly in that up to 30% of embryo transfers may be affected by endometrial receptivity factors. The endometrium is a highly specialized, hormonally regulated tissue which is only receptive to embryo communication/interaction for a self-limiting period referred to as the window of implantation. Currently, there is no way to non-invasively determine the time of optimal receptivity, with IVF transfers performed on the assumption that the WOI was sufficiently wide enough to accommodate implantation in most patients and most treatments. During this period, the endometrial epithelium acquires optimal receptivity by progressing through specific structural, functional, and morphological changes induced by pre-ovulatory estrogen and progesterone and post-ovulatory progesterone, LH, and hCG.
During the last three decades, there has been a major increase in the understanding of embryo physiology and correspondingly major improvements in the in vitro culture technologies used, in particular culture media and incubator technologies. These improvements have resulted in the culture of more good quality cleavage stage embryos and consequently blastocysts after extended culture, increasing embryo utility and the pregnancy capacity of an cycle. The increased implantation rates obtained with blastocyst transfers may be as much to do with embryo quality and stage, i.e., blastocysts have the required bi-directional communication competency needed for implantation, as with the WOI, i.e., the time of blastocyst formation and transfer coincides with the WOI of endometria. Moreover, the presently improved culture conditions may also be changing traditional embryo developmental milestones, in particular, the time to blastulation may be decreasing. An increasing number of blastocysts are being formed on day 4 of culture - ±100 hours post-insemination. Traditionally, day 4 embryos were only assessed for evidence of compaction, which is the developmental stage leading to blastulation and cell differentiation.
Zygotes or embryos that reach developmental milestones first (i.e., syngamy, early cleavage, early compaction and early blastulation) are generally believed to have increased chances of normal developmental potential. In recent artificial frozen embryo transfers (FET) in which blastocysts vitrified on day 4 of culture and transferred on P+4, with blastocysts traditionally transferred on P+5, a high rate of implantation has been observed. In addition, a greater number of these implantations resulted in clinical pregnancies (i.e., a conceptus with normal fetal heart activity). In this prospective randomised control study, the investigators will investigate whether this increased viability, is due either to embryo quality, endometrial receptivity, or a combination of the two factors by randomizing the transfer of day 5 blastocysts to P+4 or P+5.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Progesterone + 4
the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
Progesterone supplementation
artificial frozen embryo transfers
Progesterone + 5
the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
Progesterone supplementation
artificial frozen embryo transfers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Progesterone supplementation
artificial frozen embryo transfers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients who retract their consent
* patients with day 4 blastocysts frozen
* patients with no blastocysts frozen
19 Years
42 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Antalya IVF
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevin Coetzee
Scientific advisor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antalya IVF
Antalya, Antalya, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003 Jul;14(5):236-42. doi: 10.1016/s1043-2760(03)00075-4.
van de Vijver A, Polyzos NP, Van Landuyt L, Mackens S, Stoop D, Camus M, De Vos M, Tournaye H, Blockeel C. What is the optimal duration of progesterone administration before transferring a vitrified-warmed cleavage stage embryo? A randomized controlled trial. Hum Reprod. 2016 May;31(5):1097-104. doi: 10.1093/humrep/dew045. Epub 2016 Mar 22.
Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011 Jun;26(6):1270-83. doi: 10.1093/humrep/der037. Epub 2011 Apr 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AntalyaIVF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.